Financial Statements | YUNGJIN Pharmaceutical

Statement of financial position

As Of 12/31/2024, As Of 12/31/2023, As Of 12/31/2022, As Of 12/31/2021, As Of 12/31/2020

(Unit :1million KRW)

Financial Statements
	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total assets	234,258	226,601	203,083	194,095	188,100
Assets
Non-current assets	110,440	100,037	100,888	104,407	89,426
Property, plant and equipment	97,334	83,843	84,964	86,690	74,975
Intangible assets	1,684	2,315	2,679	1,442	1,565
Investment property	1,085	1,104	1,123	1,141	1,141
Fair value through other comprehensive income	505	505	505	505	5
Other financial assets			2	2	2
Long-term trade and other receivables	387	1,013	263	1,098	1,079
Deferred income tax assets	8,764	9,782	10,677	11,784	9,836
right-of-use asset	679	1,476	676	1,745	804
Current assets	123,818	126,564	102,194	89,688	98,674
Inventories	70,939	61,987	48,463	39,653	51,435
Current trade and other receivables	49,188	54,132	52,773	49,358	46,268
Advance payments	199	191	259	193	522
Prepaid expenses	57	17	17	19	21
Cash and cash equivalents	3,436	7,208	682	465	428
Other current financial assets		3,000
Current tax assets		30

Financial Statements
	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Total equity	89,803	89,632	89,870	104,885	114,432
Equity
Ordinary shares	91,446	91,446	91,446	91,446	91,446
Capital surplus	16,007	10,574	10,574	10,574	10,410
Reserve
Retained earnings	Δ17,821	Δ12,150	2,865	12,412	13.731

Financial Statements
	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total liabilities	144,455	136,968	113,213	89,210	73,668
Total equity and liabilities	234,258	226,601	203,083	194,095	188,100
Liabilities
Non-current liabilities	29,821	61,913	63,581	40,881	43,528
Long-term borrowings	4,500	17,000	27,500	1,626	3,792
convertible bonds		23,378
Long-term trade and other payables	879	847	740	35,218	226
Provision	3,678	1,834	16,689	2,428	1,142
Net defined benefit liability	20,633	18,366	18,567	1,082	38,212
Long-term lease liabilities	131	489	86	527	156
Leasehold deposits received					90
Current liabilities	114,634	75,055	49,632	48,329	30,140
Short-term borrowings			7,000	7,500	500
Current portion of long-term borrowings	32,500	25,000	4,126	2,166	2,166
Current Convertivle Bonds	32,500
Trade and other payables	35,184	30,758	35,368	34,901	25,295
Advance receipts	692	807	532	542	239
Income tax payable	309
Provision	17,996	17,476	1,996	1,980	1,272
Current lease liabilities	564	1,015	609	1,240	668

Financial Statements
	FY 2022	FY 2021	FY 2020	FY 2019
Sales	252,040	234,902	218,381	196,067	208,464
Cost of sales	171,692	162,782	Δ153,646	Δ138,131	Δ135,000
Gross profit	80,349	72,121	64,734	57,936	73,464
Selling, general and administrative expenses	71,627	69,003	Δ72,098	Δ71,814	Δ73,083
Operating profit	8,722	3,117	Δ7,363	Δ13,878	381
Other income	3,164	926	1,006	571	1,186
Other expenses	4,014	5,101	Δ15,722	Δ631	Δ1,076
Finance income	286	15	3	2	2
Finance cost	5,271	2,875	Δ737	Δ209	Δ252
Profit before income tax	2,887	Δ3,918	Δ22,813	Δ14,144	241
Income tax expense	1,654	Δ42	Δ852	Δ2,561	374
Profit for the year	1,233	Δ3,876	Δ21,961	Δ11,583	Δ133

Financial Statements
	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Total comprehensive income	171	Δ5,671	Δ15,015	Δ9,546	Δ1,319
Other comprehensive income (loss)	Δ1,062	Δ1,795	6,946	Δ2,036	Δ1,186

[Δ indicates minus(-) value]

main navigation